References
- Yu JH, Lee JW, Son BH, Kim SW, Park SK, Lee MH, et al. Characteristics of BRCA1/2 mutation-positive breast cancers in Korea: a comparison study based on multicenter data and the Korean Breast Cancer Registry. J Breast Cancer 2014;17:129-35. https://doi.org/10.4048/jbc.2014.17.2.129
- Robson ME, Boyd J, Borgen PI, Cody HS 3rd. Hereditary breast cancer. Curr Probl Surg 2001;38:387-480. https://doi.org/10.1016/S0011-3840(01)70035-4
- Seo JH, Cho DY, Ahn SH, Yoon KS, Kang CS, Cho HM, et al. BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer. Hum Mutat 2004;24:350.
- Han SA, Park SK, Ahn SH, Son BH, Lee MH, Choi DH, et al. The breast and ovarian cancer risks in Korea due to inherited mutations in BRCA1 and BRCA2: a preliminary report. J Breast Cancer 2009;12:92-9. https://doi.org/10.4048/jbc.2009.12.2.92
- Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008;108:289-96. https://doi.org/10.1007/s10549-007-9600-1
- Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-8. https://doi.org/10.1200/JCO.2008.16.6231
- Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, et al. Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat 2008;111:303-11 https://doi.org/10.1007/s10549-007-9781-7
- Panchal H, Pilewskie ML, Sheckter CC, Albornoz CR, Razdan SN, Disa JJ, et al. National trends in contralateral prophylactic mastectomy in women with locally advanced breast cancer. J Surg Oncol 2019;119:79-87. https://doi.org/10.1002/jso.25315
- Boughey JC, Attai DJ, Chen SL, Cody HS, Dietz JR, Feldman SM, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM Outcomes and Risks. Ann Surg Oncol 2016;23:3100-5. https://doi.org/10.1245/s10434-016-5443-5
- Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-8. https://doi.org/10.1200/JCO.2008.16.6231
- Lagos-Jaramillo VI, Press MF, Ricker CN, Dubeau L, Mai PL, Weitzel JN. Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Res Treat 2011;130:281-9. https://doi.org/10.1007/s10549-011-1570-7
- Gonzalez-Angulo AM, Timms KM, Liu S, Litton JK, Potter J, Lanchbury JS, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082-9. https://doi.org/10.1158/1078-0432.CCR-10-2560
- Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007;99:1683-94. https://doi.org/10.1093/jnci/djm207
- Gorski JJ, Kennedy RD, Hosey AM, Harkin DP. The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res 2009;15:1514-8. https://doi.org/10.1158/1078-0432.ccr-08-0640
- Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(15 Pt 1):4429-34. https://doi.org/10.1158/1078-0432.CCR-06-3045